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The association between sympathetic overactivity and hypertension has been 
extensively studied but the link between sympathetic excess and coronary risk has not been 
clearly defined. There is a mounting body of evidence that suggests that there is a strong 
association between the sympathetic nervous system and increased cardiac risk independent 
of hypertension which has been gleaned from observational data gathered in 
epidemiological studies and supported by clinical studies undertaken in hypertensive 
patients. 
The Tecumseh study is a large scale observational and epidemiological study 
looking at the associations and predictors of hypertension in a rural community in  
Tecumseh, Michigan. Nearly one thousand subjects were enrolled into the study and 
anthropometric, hemodynamic and metabolic data were collected at several time points. 
When first examined as children those subjects who were ultimately to develop borderline 
hypertension had significantly faster heart rates than their future normotensive counterparts 
despite having comparable blood pressures as children.( 1 )  As they aged the difference 
between the pulse rate was maintained and the blood pressure in the borderline hypertensive 
group had become elevated. When examined as adults ( 1  8-42 years) the differences in  
pulse rate and blood pressure persisted between the groups and elevated plasma 
noradrenaline was demonstrated in the hyperkinetic (high cardiac output, increased heart 
rate) hypertensive subjects. An significant increase in cardiac risk factors was found in the 
hypertensive group as a whole and also in the subpopulation of "pure" hyperkinetic 
hypertensive subjects (2) and a strong correlation between diastolic blood pressure and these 
risk factors was also found (3). This data suggests that there was a relative overactivity of 
the sympathetic nervous system present from an early age in the subjects who were to 
develop borderline hypertension and that this persisted into at least early adulthood. It also 
raises the intriguing possibility that sympathetic excess could not only be responsible for the 
blood pressure elevation in these subjects but also independently result in the increase in 
coronary risk factors. A hypothetical schema for just such an association will be described 
where excess sympathetic tone is the underlying pathophysiological state that leads to an 
increased tendency to atherosclerosis and insulin resistance as well as a propensity to 
coronary thrombosis, coronary spasm and arrhythmia's. 
Insulin resistance has been shown to be associated with hypertension (4) and is 
accompanied by an increased coronary morbidity (5). Excess sympathetic tone may 
produce insulin resistance by promoting a-adrenergic vasoconstriction and reducing the 
delivery of insulin and glucose to skeletal muscle, which is thought to be the site of insulin 
resistance in hypertension. Jamerson 's work (6) lends support to this concept when i t  was 
demonstrated that decreased blood flow in the human forearm produced by reflex activation 
of the sympathetic nervous system results in decreased glucose utilization, a condition 
analogous to insulin resistance. This type of sympathetically mediated insulin resistance 
may be compounded by the trophic effects of elevated insulin on the vascular wall (7) and 
by vascular rarefaction which has been documented to occur in hypertension (8). Further 
evidence for a role of the sympathetic nervous system in altered insulin sensitivity in 
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hypertension comes from Diebert and De Fronzo's (9) work showing that an acute decrease 
in insulin sensitivity can be produced by adrenaline infusion and from studies describing 
that chronic P-adrenergic stimulation leads to an increase in insulin resistant fast twitch 
muscle fibers in rats( 10). 
Early studies by Julius et al.( 11) found that intravenous infusion of propranolol 
caused an acute decrease in plasma volume (with an increase in hematocrit), presumably 
due to the effect of unopposed a-adrenergic tone on the post-capillary venules. Cohn et al. 
(12) found that this was not a general response to vasoconstriction when they looked at 
changes in plasma volume induced by infusion of A11 and norepinephrine. At similar levels 
of increase in blood pressure and forearm resistance norepinephrine but not angiotensin 
infusion produced a significant decrease in plasma volume. When hematocrit was 
examined in relation to blood pressure in the Tecumseh study it was found that the subjects 
with the highest hematocrit were the subjects in the hypertensive blood pressure group ( 1  3). 
These subjects had significantly increased coronary risk factors and elevated indices of 
sympathetic tone relative to their normotensive counterparts. This observational data, taken 
in the context of the previous studies lends support to the concept of increased sympathetic 
tone producing an elevated hematocrit and thus an increased risk of coronary thrombosis. 
This risk of thrombosis may be even more increased by increased platelet aggregability, as 
elevated P-thromoglobulin has been described in association with markers of increased 
sympathetic tone in hypertension (14). 
Autonomic blockade in borderline hypertensive volunteers has consistently 
demonstrated increased sympathetic tone in conjunction with a reciprocal decrease in 
parasympathetic tone (15). This decrease in parasympathetic tone tends to persist even as 
markers of sympathetic excess diminish during the course of hypertension becoming 
established. Excess sympathetic tone may predispose to the development of left ventricular 
hypertrophy by increasing blood pressure but can amplify this tendency by exerting trophic 
effects on myocytes directly (16) and by promoting renin release and increased levels of 
angiotensin I1 which can also act as a pressure independent trophic factor (17). Left 
ventricular hypertrophy is commonly seen in hypertension (18) and is associated an 
increased cardiovascular risk, predominantly due to sudden death, presumably arrythmic in 
origin. Excess ventricular ectopic activity has been demonstrated in hypertensive patients 
with and without LVH and this predisposition may be increased by the autonomic 
imbalance seen in hypertension, perhaps by decreasing the arrythmic threshold. 
Chronic elevation of the blood pressure leads to structural changes in the vascular 
wall characterized by an increase in the wall-lumen ration. These pressure induced changes 
may be accentuated by the trophic effects of increased sympathetic tone and render the 
vessel hyper-reactive to any vasoconstricting influence. Egan et al. (19) demonstrated this 
when they showed that forearm vascular resistance increased to a greater extent in  
hypertensive patients in response to norepinephrine infusion than in normotensive controls, 
and that the response was even greater in those who had elevated plasma norepinephrine 
levels. Such changes may take place in the take place in the coronary microcirculation, 
even in the absence of LVH (20), and thus make the hypertensive patient particularly prone 
to coronary artery spasm. 
Sympathetic overactivity is associated with pressure dependent and pressure 
independent effects on the cardiovascular system. The link between excess sympathetic 
tone and coronary risk is conceptually appealing and is supported by the evidence 
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accumulated to date, but is worthy of further study to more clearly define the association 
and the magnitude of risk. 
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